

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

NOTICE TO BONDHOLDERS HK\$ SETTLED RMB160,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2010

NOTICE IS HEREBY GIVEN pursuant to Section 6 of the Trust Deed dated 30 May 2007 (the Trust Deed) among Lijun International Pharmaceutical (Holding) Co., Ltd. (the "Company"), as the Issuer and The Bank of New York Mellon (formerly known as The Bank of New York), as the Trustee. As announced in the Company's announcement dated 24 April 2009, the board of directors of the Company recommended to declare a final dividend of HK\$0.01 per Share on 24 April 2009 for the year ended 31 December 2008. The Final Dividend was paid on 26 June 2009. Together with the interim dividend for the six months ended 30 June 2009 of HK\$0.02 per Share declared by the Board on 28 August 2009, the Total Current Dividend (as defined in the CB Terms and Conditions) per Share for the year ending 31 December 2009 amounts to HK\$0.03. Pursuant to the CB Terms and Conditions, the dividend falls within the definition of Capital Distribution and accordingly, the Conversion Price per Share will be adjusted from HK\$0.83 to HK\$0.81 effective from 10 October 2009 (Hong Kong time), immediately after the record date in connection with the declaration of the Interim Dividend. Apart from the Adjustment, there is no change in the terms of the Convertible Bonds. Terms used and not defined herein shall have the same meanings given to them in the Trust Deed.

By order of the Board
Sze Wing Kin, Pierre
Company Secretary

Hong Kong, 28 August 2009

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Huang Chao, Mr. Xie Yunfeng, Ms. Sun Xinglai, Mr. Wang Xianjun, Mr. Duan Wei, Ms. Zhang Guifu, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.